Core Insights - C4 Therapeutics, Inc. (CCCC) is currently outperforming its peers in the Medical sector, with a year-to-date gain of approximately 37.2% compared to the sector's average return of -5.9% [4] - The company holds a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, with the consensus estimate for full-year earnings having increased by 16.8% in the past quarter [3] - C4 Therapeutics operates within the Medical - Biomedical and Genetics industry, which includes 443 companies and is currently ranked 148 in the Zacks Industry Rank, with an average gain of 1% this year [5] Company Performance - C4 Therapeutics has shown a significant year-to-date performance, gaining 37.2%, while the Medical sector has declined by 5.9% [4] - The stock's positive performance is supported by an improving analyst sentiment, as indicated by the increase in earnings estimates [3] - Another company in the Medical sector, Align Technology (ALGN), has also outperformed the sector with a year-to-date return of 13.6% [4] Industry Context - The Medical group, which includes C4 Therapeutics, is currently ranked 8 out of 16 groups in the Zacks Sector Rank [2] - The Medical - Biomedical and Genetics industry, where C4 Therapeutics is categorized, has an average performance of 1% this year, indicating that C4 is performing significantly better than its industry peers [5] - Align Technology, belonging to the Medical - Dental Supplies industry, has a Zacks Rank of 2 (Buy) and has seen a 3.7% increase in its EPS estimate over the past three months [5][6]

Core Viewpoint - Cardinal Health's stock has shown a decline recently, but upcoming earnings are expected to reflect significant growth in both earnings per share and revenue compared to the previous year [1][2]. Group 1: Stock Performance - Cardinal Health closed at $211.87, down 2.08% from the previous day, which is less than the S&P 500's loss of 1.36% [1] - Over the past month, Cardinal Health's shares have depreciated by 4.09%, outperforming the Medical sector's loss of 5.66% but lagging behind the S&P 500's loss of 1.76% [1] Group 2: Earnings Projections - The upcoming earnings release is projected to show earnings per share (EPS) of $2.8, a 19.15% increase from the same quarter last year [2] - Revenue is expected to reach $62.42 billion, indicating a 13.74% increase compared to the same quarter of the previous year [2] - For the full year, analysts expect earnings of $10.31 per share and revenue of $259.27 billion, reflecting changes of +25.12% and +16.48% respectively from last year [3] Group 3: Analyst Estimates and Rankings - Recent changes to analyst estimates for Cardinal Health indicate positive sentiment regarding the company's business operations and profit generation capabilities [4] - The Zacks Rank system currently rates Cardinal Health as 2 (Buy), with a consensus EPS projection having moved 0.04% higher in the past 30 days [6] Group 4: Valuation Metrics - Cardinal Health is trading at a Forward P/E ratio of 20.98, which is higher than the industry average of 15.71, suggesting a premium valuation [7] - The company's PEG ratio is currently 1.39, compared to the Medical - Dental Supplies industry's average PEG ratio of 1.82, indicating a favorable growth outlook [8] Group 5: Industry Context - The Medical - Dental Supplies industry, part of the Medical sector, has a Zacks Industry Rank of 62, placing it in the top 26% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1, highlighting the potential for investment opportunities within this sector [9]

Company Performance - Align Technology (ALGN) has outperformed the Medical sector with a year-to-date return of approximately 8.5%, while the average return for Medical companies is -1.4% [4] - The Zacks Consensus Estimate for ALGN's full-year earnings has increased by 3.7% over the past quarter, indicating stronger analyst sentiment and an improving earnings outlook [4] - Biofrontera Inc. (BFRI) has also shown strong performance, with a year-to-date return of 45.6% and a 300% increase in the consensus estimate for its current year EPS over the past three months [5] Industry Ranking - Align Technology is part of the Medical - Dental Supplies industry, which consists of 15 stocks and currently ranks 50 in the Zacks Industry Rank, with this group gaining about 1% year-to-date [6] - The Medical - Biomedical and Genetics industry, which includes Biofrontera Inc., has 444 stocks and is currently ranked 144, with a year-to-date increase of 6.4% [6] Sector Overview - The Medical sector includes 925 companies and is currently ranked 10 in the Zacks Sector Rank, which evaluates the average Zacks Rank of individual stocks within the sector [2] - The Zacks Rank system identifies stocks with characteristics likely to outperform the market in the short term, with Align Technology holding a Zacks Rank of 2 (Buy) [3]

Company Overview - Adlai Nortye Ltd. Sponsored ADR (ANL) is a notable stock within the Medical sector, which comprises 926 companies, and currently ranks 9 in the Zacks Sector Rank [2] - The company is categorized under the Medical - Biomedical and Genetics industry, which includes 445 stocks and is ranked 90 in the Zacks Industry Rank [6] Performance Metrics - ANL has shown a remarkable year-to-date return of approximately 527.5%, significantly outperforming the average return of -1.7% for Medical companies [4] - Over the past three months, the Zacks Consensus Estimate for ANL's full-year earnings has increased by 33.3%, indicating improved analyst sentiment and a stronger earnings outlook [4] Comparative Analysis - Another Medical stock, Cardinal Health (CAH), has also outperformed the sector with a year-to-date increase of 6% and a Zacks Rank of 2 (Buy) [5] - Cardinal Health belongs to the Medical - Dental Supplies industry, which has a current ranking of 54 and has seen a year-to-date increase of 1.8% [7]

分组1 - The Cooper Companies reported quarterly earnings of $1.1 per share, exceeding the Zacks Consensus Estimate of $1.03 per share, and showing an increase from $0.92 per share a year ago, resulting in an earnings surprise of +7.06% [1] - The company posted revenues of $1.02 billion for the quarter ended January 2026, which was slightly below the Zacks Consensus Estimate by 0.13%, but an increase from $964.7 million in the same quarter last year [2] - The Cooper Companies has surpassed consensus EPS estimates in all four of the last quarters and has topped revenue estimates twice during the same period [2] 分组2 - The stock's immediate price movement will depend on management's commentary during the earnings call and the sustainability of earnings expectations [3] - The Cooper Companies shares have shown no significant change since the beginning of the year, compared to a 0.4% gain in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $1.07 on revenues of $1.05 billion, and for the current fiscal year, it is $4.51 on revenues of $4.32 billion [7] 分组3 - The Medical - Dental Supplies industry, to which The Cooper Companies belongs, is currently ranked in the top 23% of over 250 Zacks industries, indicating a favorable outlook for the sector [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6] - The Cooper Companies currently holds a Zacks Rank 2 (Buy), suggesting that the stock is expected to outperform the market in the near future [6]

分组1 - Staar Surgical reported quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.16 per share, compared to a loss of $0.5 per share a year ago, representing an earnings surprise of -75.51% [1] - The company posted revenues of $57.8 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 23.6%, and compared to year-ago revenues of $48.95 million [2] - Staar Surgical shares have lost about 17.5% since the beginning of the year, while the S&P 500 has gained 0.5% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.13 on $75.28 million in revenues, and $0.56 on $306.82 million in revenues for the current fiscal year [7] - The Medical - Dental Supplies industry, to which Staar Surgical belongs, is currently in the top 20% of over 250 Zacks industries, indicating a favorable outlook [8] - The Cooper Companies, another stock in the same industry, is expected to report quarterly earnings of $1.03 per share, representing a year-over-year change of +12% [9]

Core Viewpoint - Investors are evaluating Align Technology (ALGN) and West Pharmaceutical Services (WST) for potential undervalued stock opportunities in the Medical - Dental Supplies sector [1] Group 1: Company Rankings and Earnings Outlook - Both ALGN and WST currently hold a Zacks Rank of 2 (Buy), indicating positive earnings estimate revisions and an improving earnings outlook for both companies [3] - The Zacks Rank strategy targets companies with favorable earnings estimate trends, which is a key consideration for investors [2] Group 2: Valuation Metrics - ALGN has a forward P/E ratio of 16.92, while WST has a significantly higher forward P/E of 31.93, suggesting that ALGN may be undervalued compared to WST [5] - ALGN's PEG ratio is 1.68, indicating a more favorable valuation when considering expected earnings growth, compared to WST's PEG ratio of 2.71 [5] - ALGN's P/B ratio stands at 3.35, while WST's P/B ratio is 5.7, further supporting the notion that ALGN is the more attractive value option based on these metrics [6] Group 3: Value Grades - Based on various valuation metrics, ALGN has been assigned a Value grade of B, whereas WST has a Value grade of D, reinforcing the conclusion that ALGN is the superior value option at this time [6]

Core Viewpoint - Allurion Technologies, Inc. (ALUR) is being evaluated for its performance relative to its peers in the Medical sector, with a focus on its year-to-date stock performance and earnings outlook [1]. Group 1: Company Performance - Allurion Technologies, Inc. is part of the Medical group, which consists of 925 companies and holds the 8 position in the Zacks Sector Rank [2]. - The Zacks Rank for ALUR is currently 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3]. - Over the past 90 days, the Zacks Consensus Estimate for ALUR's full-year earnings has increased by 73.9%, reflecting improved analyst sentiment [4]. - Year-to-date, ALUR has returned 1.6%, matching the average gain of 1.6% for the Medical group [4]. - In comparison, McKesson (MCK), another Medical stock, has outperformed with an 18.8% increase year-to-date [4]. Group 2: Industry Context - Allurion Technologies, Inc. is categorized under the Medical - Products industry, which includes 82 companies and is currently ranked 139 in the Zacks Industry Rank [5]. - Stocks in the Medical - Products industry have experienced a decline of about 1.5% year-to-date, indicating that ALUR is performing better than its industry peers [5]. - McKesson belongs to the Medical - Dental Supplies industry, which has 15 stocks and is ranked 68, with an industry gain of +7.5% year-to-date [6].

分组1 - Dentsply International reported quarterly earnings of $0.27 per share, missing the Zacks Consensus Estimate of $0.28 per share, and showing a slight increase from $0.26 per share a year ago, resulting in an earnings surprise of -3.57% [1] - The company posted revenues of $961 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 4.45%, and showing an increase from year-ago revenues of $905 million [2] - Dentsply shares have increased approximately 12% since the beginning of the year, outperforming the S&P 500's gain of 1.5% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.36 on revenues of $889.6 million, and for the current fiscal year, it is $1.49 on revenues of $3.67 billion [7] - The Medical - Dental Supplies industry, to which Dentsply belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

分组1 - Merit Medical reported quarterly earnings of $1.04 per share, exceeding the Zacks Consensus Estimate of $0.96 per share, and showing an increase from $0.93 per share a year ago, resulting in an earnings surprise of +8.90% [1] - The company achieved revenues of $393.94 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.80%, and up from $355.16 million year-over-year [2] - Merit Medical has consistently surpassed consensus EPS estimates over the last four quarters, achieving this four times [2] 分组2 - The stock has underperformed the market, losing about 7.4% since the beginning of the year, compared to a decline of 0.1% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $0.89 on revenues of $379.6 million, and for the current fiscal year, it is $4.05 on revenues of $1.6 billion [7] - The Medical - Dental Supplies industry, to which Merit Medical belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]